Balancing Access and Outcomes at JPMorgan’s 43rd Annual Healthcare Conference by Investing.com

WARREN, N.J., Dec. 17, 2024 (GLOBE NEWSWIRE) — Tevogen Bio (Tevogen or Tevogen Bio Holdings Inc.) (Nasdaq: TVGN), a clinical-stage immunotherapy biotechnology company developing ready-to-use non-genetically modified T cells. Therapeutics to Treat Infectious Diseases and Cancer, announced today that it will host an interesting panel discussion, entitled: Leadership in Health Economics: Balancing Access and Outcomes, during the 43rd Annual JPMorgan Healthcare Conference.

This panel will bring together global thought leaders to examine critical interconnections of the healthcare ecosystem, the dynamic interplay between patient access, medical innovation, reimbursement and health policy that is often overlooked when considering individual silos. The discussion will focus on:

• Challenges and opportunities presented by American leadership in health care innovation, especially in balancing rising costs and delivering value.
• The impact of cost-containment measures, including the Inflation Control Act, on drug development and patient access.
• Implications of the new administration’s approach to US health care for the global markets and business model of the medical innovation industry.

The panelists include a senior partner at Simon-Kucher; Former Acting Under Secretary of Health, Department of Veterans Affairs and former Commissioner of the New Jersey Department of Health; Director, Rubix Health, Senior Fellow, Tufts Center for Value and Risk Evaluation in Health and Project Mentor, Johns Hopkins Tech Ventures, former CMS Chief Clinical Officer and Director of the Office of Clinical Standards; General Manager, Risk Advisory Services, Veritas; CEO of Tivogen Bio; CIO and Head of AI at Tevogen Bio.

Event details

date:
Monday, January 13, 2025

location:
Marines Memorial Hotel & Club, 609 Sutter Street, San Francisco, CA 94102, USA

Time (Pacific Time):
3:15 PM “4:00 PM” Leadership in Health Economics: Balancing Access and Outcomes
4:00 PM “6:00 PM” Reception and cocktails

For inquiries regarding additional event details, please contact [email protected].

About Tivogene Bio

Tevogen is a clinical-stage immunotherapy company that uses one of nature’s most powerful immune weapons, CD8+ cytotoxic T lymphocytes, to develop ready-to-use, non-genetically engineered precision T cell therapies to treat infectious diseases, cancers and neurological disorders. With the aim of meeting the significant unmet needs of large numbers of patients. Tevogen Leadership believes that sustainability and commercial success in today’s healthcare era depend on ensuring patient access through advanced science and innovative business models. Tevogen has reported positive safety data from its proof-of-concept clinical trial, and its major intellectual property assets are wholly owned by the Company, and are not subject to any third-party licensing agreements. These assets include three granted patents, nine pending US patents, and twelve prior US patents, two of which relate to artificial intelligence.

Tevogen is managed by a team of highly experienced industry leaders and distinguished scientists with drug development expertise and global product launch experience. Tevogen’s leadership believes that accessible, personalized therapies are the next frontier for medicine, and that disruptive business models are required to sustain medical innovation.

communication

Tivogene Biocommunications
Telephone: 1877 Tevojin, Ext. 701
[email protected]

Source: Tivogen Bio